Tissue Donor Eligibility Rule Issued; FDA Good Tissue Practices Rule Awaited
This article was originally published in The Gray Sheet
Executive Summary
FDA's tissue donor eligibility final rule will go into effect May 25, 2005, one year after its publication in the Federal Register
You may also be interested in...
Regulatory News In Brief
Tissue testing: FDA issues 1guidance on screening donors of cells, tissues and cell- and tissue-based products Feb. 28. The guidelines add three new diseases - West Nile Virus, vaccinia and sepsis - that facilities should test for to those included in a May 2004 draft version. The draft had been released in conjunction with a final donor eligibility rule developed by the agency's biologics center as part of a revamped tissue regulation framework (2"The Gray Sheet" May 24, 2004, p. 11). The new guidance also finalizes components of a 2002 draft guidance with recommendations on reducing the risk of Creutzfeldt-Jakob disease (the human version of "mad cow" disease). Further, it recommends nucleic acid amplification testing for HIV and hepatitis C in both living and cadaveric donors, rather than just the latter; modifies the agency's approach to identifying new "relevant" diseases; and adjusts procedures for communicable disease testing laboratories...
Regulatory News In Brief
Tissue testing: FDA issues 1guidance on screening donors of cells, tissues and cell- and tissue-based products Feb. 28. The guidelines add three new diseases - West Nile Virus, vaccinia and sepsis - that facilities should test for to those included in a May 2004 draft version. The draft had been released in conjunction with a final donor eligibility rule developed by the agency's biologics center as part of a revamped tissue regulation framework (2"The Gray Sheet" May 24, 2004, p. 11). The new guidance also finalizes components of a 2002 draft guidance with recommendations on reducing the risk of Creutzfeldt-Jakob disease (the human version of "mad cow" disease). Further, it recommends nucleic acid amplification testing for HIV and hepatitis C in both living and cadaveric donors, rather than just the latter; modifies the agency's approach to identifying new "relevant" diseases; and adjusts procedures for communicable disease testing laboratories...
RAPS 2004 Annual Conference In Brief
CDRH staff changes: Donna-Bea Tillman, PhD, is named Office of Device Evaluation director on a permanent basis. She had been serving as the acting director since former director Dan Schultz, MD, ascended to the CDRH helm earlier this year (1"The Gray Sheet" July 26, 2004, p. 3). Lily Ng is appointed director of executive programs; she had held the position on an acting basis for the last three months. Ng brings experience with reuse policy to her role within the Office of the Center Director. Also joining OCD on a formal basis is Joanne Less, PhD, who will assume the role of associate director for clinical research & government affairs. Less will continue to lead MDUFMA implementation, but also will intensify her involvement in coordinating intra- and intercenter human subjects' protection policies...